Table 3.
Percentage of subjects with anti-tetanus toxoid concentrations ≥0.1 IU/mL and ≥1.0 IU/mL and GMCs before and 1 month after booster dose of MenACWY-TT (booster ATP cohort).
| Prebooster | 1 Month Postbooster | |
|---|---|---|
| MenACWY-TT | ||
| ≥0.1 IU/mL, n/N (%; 95% CI) | 140/162 (86.4; 80.2–91.3) | 160/162 (98.8; 95.6–99.9) |
| ≥1.0 IU/mL, n/N (%; 95% CI) | 62/162 (38.3; 30.8–46.2) | 149/162 (92.0; 86.7–95.7) |
| GMC (95% CI) | 0.608 (0.476–0.775) | 5.057 (4.274–5.984) |
| MenACWY-PS | ||
| ≥0.1 IU/mL, n/N (%; 95% CI) | 28/51 (54.9; 40.3–68.9) | 49/51 (96.1; 86.5–99.5) |
| ≥1.0 IU/mL, n/N (%; 95% CI) | 14/51 (27.5; 15.9–41.7) | 42/51 (82.4; 69.1–91.6) |
| GMC (95% CI) | 0.252 (0.154–0.411) | 5.115 (3.073–8.514) |
ATP = according to protocol; GMC = geometric mean concentration; MenACWY-PS = quadrivalent meningococcal polysaccharide vaccine; MenACWY-TT = quadrivalent meningococcal tetanus toxoid conjugate vaccine; N = number of subjects; n = number of subjects in a given category.